World Fair for Organic Wines: the Trade Fair Will Be Back Again in Force In 2022!
14.12.2021 17:07:00 EET | Business Wire | Press release
Millésime Bio has become, over the years, the number one marketplace for professionals in the organic wine, cider, beer and spirits industries. With its digital session on 17 and 18 January 2022 and its physical fair on 24, 25 and 26 January 2022 at Montpellier Exhibition Centre, the World Fair for Organic Wines will be the first major international wine fair since the COVID crisis, a symbol that the recovery is underway.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005696/en/
(Photo: Gilles Lefrancq/Millésime Bio)
MILLESIME BIO 2022: A DOUBLE EVENT
Millésime Bio, traditionally the first wine, cider, beer and spirits trade fair of the year, will take place in two stages for this 2022 edition. A double event that will guarantee all professionals their participation while taking into account the sanitary constraints imposed in France and abroad.
The World fair for organic wines will start on 17 January for two days. Based on the model of the 2021 100% digital edition, more than 450 exhibitors and several thousand visitors will be able to exchange information and make initial contacts prior to the physical fair. On this occasion, visitors will discover in preview the medal-winners list of the Challenge Millésime Bio 2022 contest. From Monday 24 January to Wednesday 26 January, the physical fair will be an opportunity to get back to live tastings and meetings.
12/01/2022 - CHALLENGE MILLESIME BIO 2022
Every year, SudVinBio organises the largest international organic wine contest before the fair: the Challenge Millésime Bio contest. This year, the 15th edition of the contest will take place on Wednesday 12 January 2022.
NEW: Challenge Millésime Bio is opening up to international organic beers. The contest team will be accompanied by the SNBI (French National Union for Independent Breweries) to set up this tasting.
The medal-winning wines and beers will be available for tasting during the 3 days of the fair, in an area dedicated to the Challenge Millésime Bio.
More than 1,400 exhibitors from 20 countries will be there, in the heart of the number one organic vineyard in France, and will present about 40% of the French organic wine offer and a wide range of the international offer. This renewed enthusiasm consolidates Millésime Bio's position as the key marketplace that will set the trend for future trade fairs in a post health crisis context.
In parallel with the meetings with exhibitors, visitors will be able to attend a 2-day programme of conferences and Master Classes led by experts. The programme will include the results of a European IPSOS/Millésime Bio study on organic wine consumption habits.
"The Millésime Bio trade fair will welcome you from 17 January, to start with in its digital format. Following the success of last year's launch, we have perfected our online platform this year, in order to programme it a few days before our traditional physical event, which is back at last!
More than ever, we are listening to visitors and exhibitors to optimise the efficiency of this key event for buyers in the organic wine and spirits sector. Thus, a special place is reserved this year for the brewery and cider industries.”
Jeanne Fabre, President of the Millésime Bio Commission
ABOUT
MILLÉSIME BIO IS ORGANISED BY SUDVINBIO, OCCITANIA TRADE ASSOCIATION OF ORGANIC VINTNERS
SudVinBio is a non-profit association created in 1991. It is an interprofessional organisation representing producers (independent wineries and cooperatives) and merchants of organic wines in the Occitania region, France’s number one organic wine region. SudVinBio represents around 70% of the regional production of certified organic wines at the end of 2020 (around 700 000 hl). It orchestrates promotional and communication activities, protects the interests of its members, provides support for research and development as well as advisory services to its members.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005696/en/
Contact information
PRESS CONTACT
Anaïs Marchand & Fanny Courtial
+33 (0)4 72 07 42 41
fanny.courtial@clairdelune.fr – www.clairdelune.fr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom